As Ac­thar trou­bles per­sist, Mallinck­rodt in­vests in RNAi and Si­lence Ther­a­peu­tics

A day af­ter it was forced to ax an amy­otroph­ic lat­er­al scle­ro­sis study test­ing its con­tro­ver­sial Ac­thar gel, Mallinck­rodt is in­vest­ing in RNA tech­nol­o­gy to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER